Thymosin Alpha
An immune-modulating peptide derived from thymosin fraction 5. Thymosin Alpha-1 is studied for its role in T-cell maturation, immune enhancement, and anti-inflammatory effects.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How Thymosin Alpha Works
Thymosin Alpha-1 (TΞ±1) is a naturally occurring thymic peptide that acts as a potent immunomodulator, primarily by activating toll-like receptor (TLR) 2/7/9 signaling on dendritic cells and macrophages. This drives maturation of immature T-lymphocytes into functional T-helper and T-cytotoxic cells, enhancing adaptive immune responses against viral, bacterial, and tumor antigens.
- Activates TLR2/7/9 on dendritic cells and macrophages
- Triggers MyD88 signaling to NF-ΞΊB
- Induces IL-12, IFN-Ξ±, and TNF-Ξ± production
- Bridges innate and adaptive immune activation
- Promotes Th1 cytokine profile (IFN-Ξ³, IL-2)
- Enhances cytotoxic T-lymphocyte generation
- Shifts Th2-dominant immune dysregulation toward Th1
- Critical for antiviral and anti-tumor immunity
- Increases NK cell number and activity
- Enhances ADCC (antibody-dependent cellular cytotoxicity)
- Promotes NK cell IFN-Ξ³ secretion
- Augments first-line defense against virally infected cells
TΞ±1 binds TLR2, TLR7, and TLR9 on antigen-presenting cells, activating MyD88/NF-ΞΊB signaling to produce pro-immune cytokines (IL-12, IFN-Ξ±, TNF-Ξ±). These cytokines drive dendritic cell maturation and T-cell priming. TΞ±1 also directly promotes thymic T-cell differentiation from immature thymocytes, expanding functional CD4+ and CD8+ populations.
Romani L et al., J Clin Invest (2004): Thymosin alpha-1 activates dendritic cells via Toll-like receptors.
Preclinical Findings
Research Models
Clinical Data
Improved Outcomes in Sepsis, HBV, and Cancer Immunotherapy
Thymalfasin (TΞ±1) is approved in over 35 countries for use in hepatitis B/C, sepsis, and as cancer immunotherapy adjuvant. Meta-analyses of sepsis trials demonstrate significant reduction in 28-day mortality, and hepatitis trials show improved virologic response rates.
Shen YC et al., Crit Care Med (2013): Meta-analysis of thymosin alpha-1 in sepsis treatment.
Meta-analysis of 8 RCTs, n=1,197 sepsis patients
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- Approved for human use in 35+ countries with extensive safety data
- Excellent tolerability β injection-site reactions most common adverse event
- No serious immunotoxicity, autoimmunity, or hypersensitivity reactions in clinical use
- Well-tolerated in elderly and immunocompromised patients
- Endogenous thymic peptide β low immunogenic potential
Thymosin Alpha-1 is approved in many countries including Italy, China, and others. US approval limited to Zadaxin for specific indications. For research use only.
About Thymosin Alpha
An immune-modulating peptide derived from thymosin fraction 5. Thymosin Alpha-1 is studied for its role in T-cell maturation, immune enhancement, and anti-inflammatory effects.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
